Kciuk M, Marciniak B, Kontek R (2020) Irinotecan—still an important player in cancer chemotherapy: a comprehensive overview. Int J Mol Sci 21:1–21

Article  Google Scholar 

Fujii H, Ueda Y, Hirose C et al (2022) Pharmaceutical intervention for adverse events improves quality of life in patients with cancer undergoing outpatient chemotherapy. J Pharm Health Care Sci. https://doi.org/10.1186/s40780-022-00239-w

Article  PubMed  PubMed Central  Google Scholar 

Yamamoto N, Takahashi T, Kunikane H et al (2009) Phase I/II pharmacokinetic and pharmacogenomic study of UGT1A1 polymorphism in elderly patients with advanced non-small cell lung cancer treated with irinotecan. Clin Pharmacol Ther 85:149–154

Article  CAS  PubMed  Google Scholar 

Takasuna K, Hagiwara T, Hirohashi M, Kato M, Nomura M, Nagai E, Yokoi T, Kamataki T (1996) Involvement of β-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res 56:3752–3757

CAS  PubMed  Google Scholar 

Rothenberg ML, Eckardt JR, Kuhn JG et al (1996) Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 14:1128–1135

Article  CAS  PubMed  Google Scholar 

Kornblau S, Benson Iii AB, Catalano R et al (2000) Management of cancer treatment-related diarrhea: issues and therapeutic strategies. J Pain Symptom Manage 19:118–129

Article  CAS  PubMed  Google Scholar 

Regnard C, Twycross R, Mihalyo M, Wilcock A (2011) Loperamide. J Pain Symptom Manage 42:319–323

Article  PubMed  Google Scholar 

Takeda T, Sugimoto S, Matsumoto J, Iwata N, Nakamoto A, Ozaki AF, Hamano H, Ariyoshi N, Zamami Y (2024) A comparison between the adverse event profiles of patients receiving palbociclib and abemaciclib: analysis of two real-world databases. Int J Clin Pharm. https://doi.org/10.1007/s11096-023-01687-6

Article  PubMed  Google Scholar 

Matsumoto J, Iwata N, Watari S et al (2023) Adverse events of axitinib plus pembrolizumab versus lenvatinib plus pembrolizumab: a pharmacovigilance study in food and drug administration adverse event reporting system. Eur Urol Focus 9:141–144

Article  PubMed  Google Scholar 

Bergvall T, Niklas Norén G, Lindquist M (2014) VigiGrade: a tool to identify well-documented individual case reports and highlight systematic data quality issues. Drug Saf 37:65–77

Article  PubMed  Google Scholar 

Norén GN, Orre R, Bate A, Edwards IR (2007) Duplicate detection in adverse drug reaction surveillance. Data Min Knowl Discov 14:305–328

Article  Google Scholar 

Brown EG, Wood L, Wood S (1999) The medical dictionary for regulatory activities (MedDRA). Drug Saf 20:109–117

Article  CAS  PubMed  Google Scholar 

Norén GN, Sundberg R, Bate A, Edwards IR (2008) A statistical methodology for drug–drug interaction surveillance. Stat Med 27:3057–3070

Article  PubMed  Google Scholar 

OpenAI, Achiam J, Adler S et al (2023) GPT-4 technical report. https://doi.org/10.48550/arXiv.2303.08774

Groopman JE, Itri LM (1999) Chemotherapy-induced anemia in adults: incidence and treatment. JNCI: J Natl Cancer Inst 91:1616–1634

Article  CAS  PubMed  Google Scholar 

Wang-Gillam A, Li C-P, Bodoky G et al (2016) Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet 387:545–557

Article  CAS  PubMed  Google Scholar 

Nichetti F, Rota S, Ambrosini P et al (2024) NALIRIFOX, FOLFIRINOX, and gemcitabine with nab-paclitaxel as first-line chemotherapy for metastatic pancreatic cancer: a systematic review and meta-analysis. JAMA Netw Open 7:e2350756–e2350756

Article  PubMed  PubMed Central  Google Scholar 

Barbounis V, Koumakis G, Vassilomanolakis M, Demiri M, Efremidis AP (2001) Control of irinotecan-induced diarrhea by octreotide after loperamide failure. Support Care Cancer 9:258–260

Article  CAS  PubMed  Google Scholar 

Guarino A, Albano F, Ashkenazi S, Gendrel D, Hoekstra JH, Shamir R, Szajewska H (2008) European Society for Paediatric Gastroenterology, Hepatology, and Nutrition/European Society for Paediatric Infectious Diseases evidence-based guidelines for the management of acute gastroenteritis in children in Europe. J Pediatr Gastroenterol Nutr. https://doi.org/10.1097/MPG.0b013e31816f7b16

Article  PubMed  PubMed Central  Google Scholar 

Hirose K, Kozu C, Yamashita K, Maruo E, Kitamura M, Hasegawa J, Omoda K, Murakami T, Maeda Y (2012) Correlation between plasma concentration ratios of SN-38 glucuronide and sn-38 and neutropenia induction in patients with colorectal cancer and wild-type UGT1A1 gene. Oncol Lett 3:694–698

Article  CAS  PubMed  Google Scholar 

Hamano H, Mitsui M, Zamami Y et al (2019) Irinotecan-induced neutropenia is reduced by oral alkalization drugs: analysis using retrospective chart reviews and the spontaneous reporting database. Support Care Cancer 27:849–856

Article  PubMed  Google Scholar 

Matsuno O (2012) Drug-induced interstitial lung disease: mechanisms and best diagnostic approaches. Respir Res 13:39

Article  PubMed  PubMed Central  Google Scholar 

Zhang D, Chando TJ, Everett DW, Patten CJ, Dehal SS, Humphreys WG (2005) In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation. Drug Metab Dispos 33:1729

Article  CAS  PubMed  Google Scholar 

Abigerges D, Armand J-P, Chabot GG, Costa LD, Fadel E, Cote C, Hérait P, Gandia D (1994) Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea. JNCI: J Natl Cancer Inst 86:446–449

Article  CAS  PubMed  Google Scholar